Responses
Clinical trials monitor
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial
Compose a Response to This Article
Other responses
No responses have been published for this article.